XML 26 R14.htm IDEA: XBRL DOCUMENT v3.23.2
EARNINGS PER SHARE
9 Months Ended
Jun. 30, 2023
EARNINGS PER SHARE  
EARNINGS PER SHARE

6. EARNINGS PER SHARE

Basic earnings per share available to common shareholders is calculated by dividing net income available to common shareholders by the weighted average number of common shares outstanding for each period. Diluted earnings per share available to common shareholders is calculated by dividing net income available to common shareholders by the sum of the weighted average number of common shares outstanding and the weighted average dilutive equity awards.

For the three months ended June

2023

2022

    

Basic

    

Diluted

    

Basic

    

Diluted

Weighted average number of common shares outstanding

585,625

585,625

569,689

569,689

Weighted average net additional shares outstanding assuming dilutive options exercised and proceeds used to purchase treasury stock (1)

12,965

12,681

Weighted average number of shares outstanding

585,625

598,590

569,689

582,370

Net income available to common shareholders

$

3,944,379

$

3,944,379

$

6,044,808

$

6,044,808

Net earnings per share available to common shareholders

$

6.74

$

6.59

$

10.61

$

10.38

(1)Diluted earnings per share calculation includes all equity-based awards deemed to be dilutive.

For the nine months ended June

2023

2022

    

Basic

   

Diluted

   

Basic

   

Diluted

Weighted average number of common shares outstanding

584,359

584,359

567,026

567,026

Weighted average net additional shares outstanding assuming dilutive options exercised and proceeds used to purchase treasury stock (1)

9,121

14,552

Weighted average number of shares outstanding

584,359

593,480

567,026

581,578

Net income available to common shareholders

$

8,638,954

$

8,638,954

$

12,052,045

$

12,052,045

Net earnings per share available to common shareholders

$

14.78

$

14.56

$

21.25

$

20.72

(1)Diluted earnings per share calculation includes all equity-based awards deemed to be dilutive.